

Multicentre Study of HCV Status in Egyptian Patients with B-Cell Non-Hodgkin's Lymphoma with Assessment of Patients' Immunological State

Thesis

**Submitted for partial fulfillment of MD Degree
in Hematology**

By

Salma Salah El-Din Youssef

Msc. Hematology,
Faculty of Medicine – Ain Shams University

Under Supervision of

Prof. Dr. Mohamed Osman Azzazi

Professor of Internal Medicine and Hematology
Faculty of Medicine – Ain Shams University

Prof. Dr. Mohamed Abdel Maaboud Mohamed

Professor of Internal Medicine and Gastroenterology
Faculty of Medicine – Ain Shams University

Prof. Dr. Mohamed Mahmoud Mousa

Professor of Internal Medicine and Hematology
Faculty of Medicine – Ain Shams University

Dr. Rasha Magdy Mohamed

Lecturer of Internal Medicine and Hematology
Faculty of Medicine – Ain Shams University

**Faculty of Medicine
Ain Shams University
2017**



وَأَنْزَلَ اللَّهُ عَلَيْكَ
الْكِتَابَ وَالْحِكْمَةَ
وَعَلَّمَكَ مَا لَمْ تَكُنْ
تَعْلَمُ وَكَانَ فَضْلُ اللَّهِ
عَلَيْكَ عَظِيمًا

صِرَاقُ اللَّهِ الْعَظِيمِ

سُورَةُ النِّسَاءِ (الْأَيَةُ ١١٢)



*First and above all thanks to **ALLAH**.*

I would like to express my endless gratitude and appreciation to my eminent professor,

***Prof. Dr. Mohamed Osman Azzazi**, Professor of Internal Medicine and Hematology, Faculty of Medicine - Ain Shams University, for giving me the honor to work under her supervision and from whom I did learn a lot. He encouraged me, removed all the obstacles from my way and pushed me to achieve success.*

*My sincere thanks to **Prof. Dr. Mohamed Abdel Maaboud Mohamed**, Professor of Internal Medicine and Gastroenterology, Faculty of Medicine - Ain Shams University, for his continuous guidance, honest help and endurance that made this thesis come to light.*

*I would also like to express my gratefulness to **Prof. Dr. Mohamed Mahmoud Mousa**, Professor of Internal Medicine and Hematology, Faculty of Medicine - Ain Shams University, for his precious advice and support throughout this whole work.*

*I thank also, **Dr. Rasha Magdy Mohamed**, Lecturer of Internal Medicine and Hematology, Faculty of Medicine - Ain Shams University, for her efforts in this study.*

Salma Salah El-Din Youssef

List of Contents

<i>Title</i>	<i>Page No.</i>
List of Abbreviations.....	ii
List of Tables	vi
List of Figures	ix
Introduction	1
Aim of the work	5
<u>Review of Literature</u>	
• Chapter (1) : Non-Hogjkin Lymphoma	6
• Chapter (2): Hepatitis C Virus	18
• Chapter (3): Role of Hepatitis C Viruses Infection in Lymphomagenesis.....	66
• Chapter (4): HCV Related Non–Hodgkin Lymphoma	87
Patients and Methods	108
Results	121
Discussion	176
Summary	199
Conclusion.....	205
Recommendations	206
References	207
Arabic Summary	--

List of Abbreviations

AASLD	American Association for the Study of Liver Diseases
AMPL	Amplification
ARFP	Alternate reading frame protein
AVT	Anti viral therapy
BOC	Boceprevir
CHC	Chronic hepatitis C infection
CHOP	Cyclophosphamide / Doxorubicin / Vincristine / Prednisolone
CLL	Chronic lymphocytic leukemia
CMIA	Chemiluminescent microparticulate immunoassay
CONJ	Conjugate
CS	Cryoglobulinemic syndrome
CTRL	Control
DAA s	Direct acting antivirals
DFS	Disease free survival
DLBCL	Diffuse large B-cell lymphoma
EBV	Epstien Barr Virus
EIA	Enzyme immunoassay
EMCV	Encephalomyoconditis Virus
FGT	Female genital tract
FL	Follicular lymphoma
GC	Germinal centre

List of Abbreviations Cont...

GIT	Gastrointestinal tract
HAV	Hepatitis A Virus
HBV	Hepatitis B Virus
HCC	Hepatocellular carcinoma
HCV – E2	HCV envelope glycoprotein
HCV	Hepatitis C Virus
HCV cc	cell-cultured HCV
HIV	Human immunodeficiency virus
HTLV – 1	Human T-cell lymphoma Virus – 1
IgHC	Immunoglobulin heavy chain
IGHV	Immunoglobulin heavy chain variable region
Igs	Immunoglobulins
IL 2	Interleukin 2
IND	Investigational new drug
IRES	International ribosomal entry site
Irf – 1	interferon regulatory factor – 1
KDa	Kilo Dalton
LDH	Lactate dehydrogenase
LIA	Line immunoassay
LiPA	Line Probe Assay
LPD	lymphoproliferative disorders
LPL	Lymphoplasmacytic lymphoma

List of Abbreviations Cont...

MALT	Mucosa associated lymphoid tissue
MC	Mixed cryoglobulinemia
MGP s	Magnetic glass particles
MGUS	Monoclonal gammopathy of undetermined significance
MLV	Murine leukemia virus
MZL	Marginal zone lymphoma
NAAT	Nucleic acid amplification test
NHL	Non Hodgkin lymphoma
NIH	National Institute of Health
NMZL	Nodal marginal zone lymphoma
NTP	Nucleoside triphosphate
OPD	O – Phenylenediamine
OS	Overall survival
OTC	Over the counter
PAS	Periodic acid shef
PAT	Parental antischistosomal therapy
PCR	Polymerase Chain Reaction
Peg-IFN	Pegylated interferon
PFS	Progression free survival
PIRR	Pegylated interferon / Ribavirin / Rituximab
Rbv	Ribavirin
RF	Rheumatoid factor

List of Abbreviations Cont...

RIBA	Recombinent immunoblot assay
RT	Reverse Transcriptase
RTX	Rituximab
SMZL	Splenic marginal zone lymphoma
SOF	Sofosbuvir
SOP	Standard Operating Procedure
SVR	Sustained virologic response
TNAIK	Total Nucleic Acid Isolation Kit
TVR	Telaprevir
U.S	United States
ULN	Upper limit of normal
UTR	Untranslated Region
WM	Waldenstrom macroglobulinemia

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
------------------	--------------	-----------------

Table of Review:

Table A:	Lymphoma classification.	8
Table B:	Main direct acting antiviral targets and drug classes.	52

Table of Results:

Table (1):	Showing descriptive data of NHL patients (Patient Group) according to age, sex, viral load, histopathologic subtypes and HCV infection status	122
Table (2):	Showing descriptive data of solid malignancies group (Control group A) according to age, sex, viral load, type of solid malignancy and HCV infection status.	123
Table (3):	Showing descriptive data of HCV-ve chronic liver disease patients (Control Group B) according to age, sex, type of liver disease and HCV infection status.	124
Table (4):	Showing descriptive data of control healthy subjects (Control Group C) according to age, sex and HCV infection status.	124
Table (5):	Showing descriptive data of NHL patients according to CBC counts, S.albumin, S.bilirubin, prothrombin concentration, LDH, β 2 microglobulin and serum immunoglobulins levels.....	125
Table (6):	Showing descriptive data of solid malignancies patients according to CBC counts, S.albumin, S.bilirubin, prothrombin concentration, LDH, β 2 microglobulin and serum immunoglobulins levels.	126
Table (7):	Showing descriptive data of HCV-ve chronic liver disease patients according to CBC counts, S.albumin, S.bilirubin, prothrombin concentration, LDH, β 2 microglobulin and serum immunoglobulins levels.	127
Table (8):	Comparison between NHL patients and solid malignancy patients (Control group A) as regard age, sex, viral load and HCV infection status.....	128
Table (9):	Comparison between patient and control groups A and B as regards some lab data.	129

List of Tables (Cont...)

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (10):	Comparison between HCV positive and HCV negative patients of NHL patient group as regard some lab data.....	130
Table (11):	Comparison between HCV positive and negative patients of control group A (Solid malignancies) as regard lab data. ...	131
Table (12):	Relation between HCV status and age, sex and histopathologic subtypes of NHL among NHL patientst	132
Table (13):	Relation between HCV status and age, sex and histopathology of solid malignancies among solid malignancies patients.....	133
Table (14):	Correlation between age, sex and histopathology of NHL among NHL patients.....	134
Table (15):	Correlation between age, sex and histopathology of solid malignancies among solid malignancies patients	135
Table (16):	Correlation between type of liver disease and age and sex amongHCV-ve chronic liver disease patients	136
Table (17):	Correlations between age and viral load among NHL patients.....	137
Table (18):	Correlations between age and viral load among Control goup A patients (Solid malignancies)	138
Table (19):	Relation between viral load, sex and histopathology of NHL in NHL patient group.....	139
Table (20):	Correlation between viral load , sex and histopathology of solid malignancies in Control group A	140
Table (21):	Correlations between viral load and CBC counts among NHL patients.....	141
Table (22):	Correlations between viral load and CBC counts among Control group A (solid malignancies).	142
Table (23):	Correlations between viral load and liver functions among NHL patients	143

List of Tables (Cont...)

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (24):	Correlations between viral load and liver functions among solid malignancies patients.....	144
Table (25):	Correlations between viral load and S.β2 microglobulin, S.cryoglobulin and S.immunoglobulins among NHL patients	145
Table (26):	Correlations between viral load and S.β2 microglobulin, S.cryoglobulin and S.immunoglobulins among solid malignancies patients (Control group A).....	146
Table (27):	Comparison between NHL group and control groups A and B as regards serum cryoglobulin status.....	147
Table (28):	Comparison between HCV positive and HCV negative patients of NHL group as regard serum cryoglobulin status.	148
Table (29):	Comparison between HCV positive and HCV negative patients of control group A (Solid malignancies) as regard serum cryoglobulin status.....	149

List of Figures

<i>Fig. No.</i>	<i>Title</i>	<i>Page No.</i>
-----------------	--------------	-----------------

Figure of Review:

Figure (A):	HCV genome organization, polyprotein processing and p7 precursors.....	19
Figure (B):	A simplified diagram of the HCV replication cycle.	25
Figure (C):	Clinical manifestation of cryoglobulinemic vasculitis	73

Figure of Results:

Fig. (1):	Distribution of different NHL patients according to histopathologic subtypes.	150
Fig. (2):	Distribution of different solid malignancies patients according to the site of solid malignancy.	151
Fig. (3):	Distribution of control group B cases according to the type of chronic liver disease.....	152
Fig. (4):	Demonstration of HCV infection status (positivity) in NHL cases.	153
Fig. (5):	Demonstration of HCV infection status among different NHL histopathologies in NHL patient group	154
Fig. (6):	HCV infection status (positivity) in control group A.....	155
Fig. (7):	Demonstration of HCV infection status among different solid malignancies cases in control group A.....	156
Fig. (8):	Comparison between NHL group and control group A as regard HCV infection status	157
Fig. (9):	Comparison between different NHL histopathologies as regard viral load	158
Fig. (10):	Comparison between NHL group and control group A as regard viral load	159
Fig.(11):	Correlation between viral load and platelet count in NHL patient group	160
Fig. (12):	Correlation between viral load and prothrombin concentration in NHL patient group.	161
Fig. (13):	Correlation between viral load and S.beta 2 microglobulin in NHL patient group.	162

List of Figures (Cont...)

<i>Fig. No.</i>	<i>Title</i>	<i>Page No.</i>
Fig. (14):	Correlation between viral load and S. IgM level in NHL patient group.....	163
Fig. (15):	Comparison between NHL, control group A and control group B as regard S.LDH and S.beta 2 microglobulin	164
Fig. (16):	Comparison between NHL group, control group A and control group B as regard S.IgM level	165
Fig. (17):	Comparison between NHL group, control group A and control group B as regard S.IgG level	166
Fig. (18):	Comparison between NHL group, control group A and control group B as regard S.IgA level	167
Fig. (19):	Comparison between HCV positive and HVC negative patients of NHL patient group as regard WBC count, Hb level and Platelet count	168
Fig. (20):	Comparison between HCV positive and HCV negative patients of control group A (solid malignancies) as regard WBC count, Hemoglobin level and Platelet count.	169
Fig. (21):	Comparison between HCV positive and HCV negative patients of NHL group as regard S.albumin, S.bilirubin, S.LDH and S.beta 2 microglobulin.	170
Fig. (22):	Comparison between HCV positive and HCV negative patients of control group A (solid malignancies) as regard S.albumin, S.bilirubin, S.LDH and S.beta 2 microglobulin	171
Fig. (23):	Comparison between HCV positive and HCV negative patients of NHL patient group as regard serum cryoglobulin status.....	172
Fig. (24):	Comparison between HCV positive and HCV negative patients of control group A (solid malignancies) as regard serum cryoglobulin status.....	173
Fig. (25):	Comparison between HCV positive and HCV negative patients of NHL group as regard serum immunoglobulins levels.	174
Fig. (26):	Comparison between HCV positive and HCV negative patients of control group A (solid malignancies) as regard serum immunoglobulins levels.....	175

WHO Classification of Lymphoid Neoplasms (2017)

WHO Classification of the Mature B-Cell, T-Cell, and NK-Cell Neoplasms

Mature B-Cell Neoplasms

- Chronic lymphocytic leukemia/small lymphocytic lymphoma
- Monoclonal B-cell lymphocytosis
- B-cell prolymphocytic leukemia
- Splenic marginal zone lymphoma
- Hairy cell leukemia
- *Splenic lymphoma/leukemia, unclassifiable* Splenic diffuse red pulp small B-cell lymphoma* Hairy cell leukemia-variant**
- Lymphoplasmacytic lymphoma Waldenström's macroglobulinemia
- Monoclonal gammopathy of undetermined significance (MGUS), IgM
- Mu heavy chain disease
- Gamma heavy chain disease
- Alpha heavy chain disease
- Monoclonal gammopathy of undetermined significance (MGUS), IgG/A
- Plasma cell myeloma

* Provisional entities are listed in italics

- Solitary plasmacytoma of bone
- Extraosseous plasmacytoma
- Monoclonal immunoglobulin deposition diseases
- Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT type)
- Nodal marginal zone lymphoma *Pediatric nodal marginal zone lymphoma**

- Follicular lymphoma

In situ follicular neoplasia Duodenal-type follicular lymphoma

- Pediatric-type follicular lymphoma
- *Large B-cell lymphoma with IRF4 rearrangement*
- Primary cutaneous follicle center lymphoma
- Mantle cell lymphoma

In situ mantle cell neoplasia

- Diffuse large B-cell lymphoma (DLBCL), NOS Germinal center B-cell type

Activated B-cell type

- T-cell/histiocyte-rich large B-cell lymphoma
- Primary DLBCL of the central nervous system (CNS)
- Primary cutaneous DLBCL, leg type
- EBV-positive DLBCL, NOS
- *EBV-positive mucocutaneous ulcer**
- DLBCL associated with chronic inflammation

* Provisional entities are listed in italics